Last updated: October 02, 2026

Application No. 18/258,343

Therapeutic RNA for Treating Cancer

Final Rejection

Filed

Jun 20, 2023

Priority

Dec 21, 2020 — EU PCT/EP2020/087468 +2 more

Examiner

PUTTLITZ, KARL J

Art Unit

1646

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Biontech SE

OA Round

2 (Final)

Interview Optional

— +18.6% interview lift. Examiner has a relatively high allowance rate (69%); +18.6% interview lift. A written response may suffice.

Based on 1432 resolved cases, 2023–2026

Examiner Intelligence

PUTTLITZ, KARL J View full profile →

Grants 69% — above average

Career Allowance Rate

990 granted / 1432 resolved

+9.1% vs TC avg

Strong +19% interview lift

Without

With

+18.6%

Interview Lift

resolved cases with interview

Typical timeline

2y 6m

Avg Prosecution

62 currently pending

Career history

1487

Total Applications

across all art units

Statute-Specific Performance

§101

1.6%

-38.4% vs TC avg

§103

36.6%

-3.4% vs TC avg

§102

11.3%

-28.7% vs TC avg

§112

28.3%

-11.7% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1432 resolved cases

Prosecution Timeline

Jun 20, 2023

Application Filed

Mar 23, 2026

Non-Final Rejection mailed

Jun 03, 2026

Response Filed

Aug 17, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/749,763

Patent 12741039

Urokinase Plasminogen Activator Receptor-Targeted Radiopharmaceutical

4y 4m to grant Granted Sep 22, 2026

18/844,818

Patent 12734244

ANTIBODY-DRUG CONJUGATES AND THEIR USES

2y 0m to grant Granted Sep 15, 2026

16/885,519

Patent 12723130

DIOL COMPOSITION AND POLYESTER

6y 3m to grant Granted Sep 01, 2026

18/030,689

Patent 12721906

KIDNEY TARGETED DELIVERY OF DRUGS

3y 4m to grant Granted Sep 01, 2026

18/255,332

Patent 12721893

Antigen-Binding Protein Targeting CD70 and Use Thereof

3y 3m to grant Granted Sep 01, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

69%

Grant Probability

88%

With Interview (+18.6%)

2y 6m (~0m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 1432 resolved cases by this examiner. Grant probability derived from career allowance rate.